Loading
Bemarituzumab is an antibody against FGFR2b, a growth receptor overproduced in about a third of stomach cancers. It improved survival early in its phase 3 trial, but the gain faded with longer follow-up.
Afucosylated IgG1 blocking FGFR2b ligand binding and enhancing ADCC. FORTITUDE-101: interim OS 17.9 vs 12.5 months (HR 0.61) in FGFR2b ≥10% 2+/3+ tumours, attenuated at updated analysis (ESMO 2025). Corneal adverse events are frequent. FORTITUDE-102 adds nivolumab. The regulatory path was still uncertain in September 2026.
Blocks FGF ligand binding to FGFR2b and recruits NK-mediated ADCC. Connects to FGFR2.
1.Bemarituzumab binds the FGFR2b receptor on tumour cells
Compare all products across the US, EU, UK, Japan, China and Australia →
| Adverse event |
|---|
| Corneal adverse events (keratitis, dry eye) |
| Stomatitis |
Frequent; dose-limiting. Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Bemarituzumab" OR ABSTRACT:"Bemarituzumab" OR TITLE:"FPA144" OR ABSTRACT:"FPA144") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Bemarituzumab, not a curated reading list.
Shares FORTITUDE-101, FGFR2, Gastric & gastro-oesophageal junction cancer.
Shares Amgen, Monoclonal antibodies.
Shares Amgen, Monoclonal antibodies.
Shares RAS / RAF / MEK / ERK (MAPK), Gastric & gastro-oesophageal junction cancer.
Shares Amgen, Monoclonal antibodies.
Shares RAS / RAF / MEK / ERK (MAPK), Gastric & gastro-oesophageal junction cancer.